Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of “Moderate Buy” by Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has received an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $39.00.

Several analysts have recently issued reports on ARTV shares. Cantor Fitzgerald upped their target price on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Finally, Wedbush raised their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV opened at $9.78 on Friday. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $14.53. The firm has a market cap of $241.76 million, a price-to-earnings ratio of -2.76 and a beta of 2.86. The company has a fifty day moving average price of $8.19 and a 200-day moving average price of $5.58.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, research analysts anticipate that Artiva Biotherapeutics will post -2.45 EPS for the current fiscal year.

Insider Transactions at Artiva Biotherapeutics

In related news, Director Ra Capital Management, L.P. acquired 6,510,416 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $11.52 per share, for a total transaction of $74,999,992.32. Following the completion of the acquisition, the director owned 15,203,995 shares of the company’s stock, valued at approximately $175,150,022.40. This represents a 74.89% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 21.40% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

Large investors have recently added to or reduced their stakes in the stock. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the third quarter worth about $41,000. Bank of America Corp DE increased its holdings in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the second quarter worth about $53,000. Qube Research & Technologies Ltd purchased a new stake in Artiva Biotherapeutics during the second quarter worth about $58,000. Finally, Jane Street Group LLC bought a new position in Artiva Biotherapeutics during the second quarter worth about $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.